Results of recent studies that we supported focusing on vaccination against Streptococcus pneumoniae, a Gram-positive bacterium that is responsible for the majority of community-acquired pneumonia, were recently published, providing more evidence for health departments to use when developing their pediatric vaccination strategies.
As the site manager for PREVAIL, Victor puts his empathy and passion for helping people to work by responding to operations requests, evaluating challenges, holding daily meetings with staff, and verifying and approving daily financial disbursements.
Maccarthy looks forward to working with diverse groups of people and perspectives on various issues and is passionate not only for improving human resources management but also for connecting talented individuals with a rewarding workplace.
Dr. Johnson carries the responsibility of many roles as part of the PREVAIL team, including being a licensed Liberian medical doctor and providing insights, expertise and guidance to her colleagues on a daily basis.
Expert panelists from the FHI Clinical roundtable at the Virtual Global Forum on TB Vaccines conference shared their thoughts on the new WHO guidelines for TPT and the implications for TB vaccine development. See what they had to say here.
In April, the Director of the Maryland Center for Health Equity’s Dr. Stephen B. Thomas partnered with FHI Clinical for a frank conversation by experts about COVID and how to encourage Brown and Black communities to participate in clinical research.
To debunk some myths around COVID-19 and the vaccine, a powerhouse panel of distinguished physicians, public health professionals and other leaders had a frank video discussion about the effects of COVID-19 on Black and brown communities.
The FHI Clinical project team supported site monitoring, site management and project management to assist the University of Notre Dame investigators achieve a level of rigor not typically required for a non-medical product in their double-blinded, randomized-cluster, placebo-controlled clinical trial of a spatial repellent against mosquitoes for malaria prevention.
The industry’s response to outbreaks like COVID-19 will continue to push advances in technology and influence the way we conduct clinical research. Challenges we’ve faced trying to adhere to impossible timelines and budgets have solidified the need for a technology platform that includes three main characteristics: unified, modular and cloud-based.
In this blog post, we share information about Liberia’s efforts to recover from the Ebola outbreak, including information presented by Bernice Dahn, Vice President of College of Health Sciences at the University of Liberia.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA